Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 therapies (MA review TA704 and TA862) [ID5121]
In development
Reference number: GID-TA11674
Expected publication date:
Please note this evaluation has been combined with ID6309. The evaluation will continue under ID5121.